Universal Technical Institute, Inc. (UTI) Stock Competitors & Peer Comparison
See (UTI) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTI | $40.17 | -6.49% | 2.2B | 51.79 | $0.76 | N/A |
| EDU | $46.38 | +2.53% | 7.2B | 16.67 | $2.70 | +2.68% |
| TAL | $9.37 | -0.43% | 5.6B | 9.96 | $0.92 | N/A |
| GHC | $1,148.76 | +1.31% | 4.9B | 16.88 | $67.61 | +0.65% |
| LAUR | $36.32 | +6.31% | 4.9B | 18.83 | $1.87 | N/A |
| LRN | $99.14 | +2.49% | 4.1B | 15.21 | $6.39 | N/A |
| LOPE | $151.15 | +1.72% | 4B | 18.73 | $7.99 | N/A |
| ATGE | $106.64 | +1.49% | 3.9B | 15.71 | $6.79 | N/A |
| MH | $12.83 | +7.72% | 2.5B | -35.03 | -$0.37 | N/A |
| PRDO | $35.21 | +3.30% | 2.2B | 13.10 | $2.62 | +1.76% |
Stock Comparison
UTI vs EDU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, EDU has a market cap of 7.2B. Regarding current trading prices, UTI is priced at $40.17, while EDU trades at $46.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas EDU's P/E ratio is 16.67. In terms of profitability, UTI's ROE is +0.13%, compared to EDU's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to EDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check EDU's competition here
UTI vs TAL Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TAL has a market cap of 5.6B. Regarding current trading prices, UTI is priced at $40.17, while TAL trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas TAL's P/E ratio is 9.96. In terms of profitability, UTI's ROE is +0.13%, compared to TAL's ROE of +0.15%. Regarding short-term risk, UTI is more volatile compared to TAL. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check TAL's competition here
UTI vs GHC Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GHC has a market cap of 4.9B. Regarding current trading prices, UTI is priced at $40.17, while GHC trades at $1,148.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GHC's P/E ratio is 16.88. In terms of profitability, UTI's ROE is +0.13%, compared to GHC's ROE of +0.06%. Regarding short-term risk, UTI is more volatile compared to GHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GHC's competition here
UTI vs LAUR Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LAUR has a market cap of 4.9B. Regarding current trading prices, UTI is priced at $40.17, while LAUR trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LAUR's P/E ratio is 18.83. In terms of profitability, UTI's ROE is +0.13%, compared to LAUR's ROE of +0.25%. Regarding short-term risk, UTI is more volatile compared to LAUR. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LAUR's competition here
UTI vs LRN Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LRN has a market cap of 4.1B. Regarding current trading prices, UTI is priced at $40.17, while LRN trades at $99.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LRN's P/E ratio is 15.21. In terms of profitability, UTI's ROE is +0.13%, compared to LRN's ROE of +0.20%. Regarding short-term risk, UTI is more volatile compared to LRN. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LRN's competition here
UTI vs LOPE Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LOPE has a market cap of 4B. Regarding current trading prices, UTI is priced at $40.17, while LOPE trades at $151.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LOPE's P/E ratio is 18.73. In terms of profitability, UTI's ROE is +0.13%, compared to LOPE's ROE of +0.30%. Regarding short-term risk, UTI is more volatile compared to LOPE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LOPE's competition here
UTI vs ATGE Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ATGE has a market cap of 3.9B. Regarding current trading prices, UTI is priced at $40.17, while ATGE trades at $106.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas ATGE's P/E ratio is 15.71. In terms of profitability, UTI's ROE is +0.13%, compared to ATGE's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to ATGE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ATGE's competition here
UTI vs MH Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, MH has a market cap of 2.5B. Regarding current trading prices, UTI is priced at $40.17, while MH trades at $12.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas MH's P/E ratio is -35.03. In terms of profitability, UTI's ROE is +0.13%, compared to MH's ROE of -0.13%. Regarding short-term risk, UTI is more volatile compared to MH. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check MH's competition here
UTI vs PRDO Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, PRDO has a market cap of 2.2B. Regarding current trading prices, UTI is priced at $40.17, while PRDO trades at $35.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas PRDO's P/E ratio is 13.10. In terms of profitability, UTI's ROE is +0.13%, compared to PRDO's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to PRDO. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check PRDO's competition here
UTI vs STRA Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, STRA has a market cap of 1.8B. Regarding current trading prices, UTI is priced at $40.17, while STRA trades at $81.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas STRA's P/E ratio is 14.25. In terms of profitability, UTI's ROE is +0.13%, compared to STRA's ROE of +0.08%. Regarding short-term risk, UTI is more volatile compared to STRA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check STRA's competition here
UTI vs LINC Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LINC has a market cap of 1.5B. Regarding current trading prices, UTI is priced at $40.17, while LINC trades at $47.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LINC's P/E ratio is 64.42. In terms of profitability, UTI's ROE is +0.13%, compared to LINC's ROE of +0.12%. Regarding short-term risk, UTI is more volatile compared to LINC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LINC's competition here
UTI vs DAO Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, DAO has a market cap of 1.4B. Regarding current trading prices, UTI is priced at $40.17, while DAO trades at $12.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas DAO's P/E ratio is 132.67. In terms of profitability, UTI's ROE is +0.13%, compared to DAO's ROE of -0.03%. Regarding short-term risk, UTI is more volatile compared to DAO. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check DAO's competition here
UTI vs AFYA Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AFYA has a market cap of 1.3B. Regarding current trading prices, UTI is priced at $40.17, while AFYA trades at $14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas AFYA's P/E ratio is 8.77. In terms of profitability, UTI's ROE is +0.13%, compared to AFYA's ROE of +0.16%. Regarding short-term risk, UTI is more volatile compared to AFYA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check AFYA's competition here
UTI vs PXED Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, PXED has a market cap of 1.1B. Regarding current trading prices, UTI is priced at $40.17, while PXED trades at $31.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas PXED's P/E ratio is 11.20. In terms of profitability, UTI's ROE is +0.13%, compared to PXED's ROE of +0.21%. Regarding short-term risk, UTI is more volatile compared to PXED. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check PXED's competition here
UTI vs APEI Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, APEI has a market cap of 961.3M. Regarding current trading prices, UTI is priced at $40.17, while APEI trades at $53.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas APEI's P/E ratio is 27.15. In terms of profitability, UTI's ROE is +0.13%, compared to APEI's ROE of +0.14%. Regarding short-term risk, UTI is more volatile compared to APEI. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check APEI's competition here
UTI vs ARCE Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ARCE has a market cap of 927.4M. Regarding current trading prices, UTI is priced at $40.17, while ARCE trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas ARCE's P/E ratio is -73.58. In terms of profitability, UTI's ROE is +0.13%, compared to ARCE's ROE of +0.02%. Regarding short-term risk, UTI is more volatile compared to ARCE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ARCE's competition here
UTI vs COUR Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, COUR has a market cap of 900.7M. Regarding current trading prices, UTI is priced at $40.17, while COUR trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas COUR's P/E ratio is -14.00. In terms of profitability, UTI's ROE is +0.13%, compared to COUR's ROE of -0.10%. Regarding short-term risk, UTI is more volatile compared to COUR. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check COUR's competition here
UTI vs QSG Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, QSG has a market cap of 822.3M. Regarding current trading prices, UTI is priced at $40.17, while QSG trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas QSG's P/E ratio is 5.54. In terms of profitability, UTI's ROE is +0.13%, compared to QSG's ROE of +0.24%. Regarding short-term risk, UTI is less volatile compared to QSG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check QSG's competition here
UTI vs REDU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, REDU has a market cap of 730.3M. Regarding current trading prices, UTI is priced at $40.17, while REDU trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas REDU's P/E ratio is -23.04. In terms of profitability, UTI's ROE is +0.13%, compared to REDU's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to REDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check REDU's competition here
UTI vs UDMY Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, UDMY has a market cap of 677.3M. Regarding current trading prices, UTI is priced at $40.17, while UDMY trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas UDMY's P/E ratio is -92.60. In terms of profitability, UTI's ROE is +0.13%, compared to UDMY's ROE of -0.03%. Regarding short-term risk, UTI is more volatile compared to UDMY. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check UDMY's competition here
UTI vs GOTU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GOTU has a market cap of 523M. Regarding current trading prices, UTI is priced at $40.17, while GOTU trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GOTU's P/E ratio is -5.70. In terms of profitability, UTI's ROE is +0.13%, compared to GOTU's ROE of -0.30%. Regarding short-term risk, UTI is more volatile compared to GOTU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GOTU's competition here
UTI vs KLC Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, KLC has a market cap of 457.7M. Regarding current trading prices, UTI is priced at $40.17, while KLC trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas KLC's P/E ratio is -1.08. In terms of profitability, UTI's ROE is +0.13%, compared to KLC's ROE of -0.55%. Regarding short-term risk, UTI is more volatile compared to KLC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check KLC's competition here
UTI vs VSTA Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, VSTA has a market cap of 394M. Regarding current trading prices, UTI is priced at $40.17, while VSTA trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas VSTA's P/E ratio is 4.22. In terms of profitability, UTI's ROE is +0.13%, compared to VSTA's ROE of +0.10%. Regarding short-term risk, UTI is more volatile compared to VSTA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VSTA's competition here
UTI vs VTRU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, VTRU has a market cap of 304.2M. Regarding current trading prices, UTI is priced at $40.17, while VTRU trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas VTRU's P/E ratio is 15.91. In terms of profitability, UTI's ROE is +0.13%, compared to VTRU's ROE of +0.05%. Regarding short-term risk, UTI is more volatile compared to VTRU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VTRU's competition here
UTI vs LGCY Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LGCY has a market cap of 142.2M. Regarding current trading prices, UTI is priced at $40.17, while LGCY trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LGCY's P/E ratio is 18.73. In terms of profitability, UTI's ROE is +0.13%, compared to LGCY's ROE of +0.19%. Regarding short-term risk, UTI is more volatile compared to LGCY. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LGCY's competition here
UTI vs SKIL-WT Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, SKIL-WT has a market cap of 138.5M. Regarding current trading prices, UTI is priced at $40.17, while SKIL-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas SKIL-WT's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to SKIL-WT's ROE of -7.09%. Regarding short-term risk, UTI is less volatile compared to SKIL-WT. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check SKIL-WT's competition here
UTI vs CHGG Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, CHGG has a market cap of 124.8M. Regarding current trading prices, UTI is priced at $40.17, while CHGG trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas CHGG's P/E ratio is -1.41. In terms of profitability, UTI's ROE is +0.13%, compared to CHGG's ROE of -0.63%. Regarding short-term risk, UTI is more volatile compared to CHGG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check CHGG's competition here
UTI vs YOUL Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, YOUL has a market cap of 78.3M. Regarding current trading prices, UTI is priced at $40.17, while YOUL trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas YOUL's P/E ratio is 11.44. In terms of profitability, UTI's ROE is +0.13%, compared to YOUL's ROE of +0.29%. Regarding short-term risk, UTI is less volatile compared to YOUL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check YOUL's competition here
UTI vs BEDU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, BEDU has a market cap of 66.8M. Regarding current trading prices, UTI is priced at $40.17, while BEDU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas BEDU's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.13%, compared to BEDU's ROE of -1.03%. Regarding short-term risk, UTI is more volatile compared to BEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check BEDU's competition here
UTI vs SKIL Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, SKIL has a market cap of 54.8M. Regarding current trading prices, UTI is priced at $40.17, while SKIL trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas SKIL's P/E ratio is -0.38. In terms of profitability, UTI's ROE is +0.13%, compared to SKIL's ROE of -7.09%. Regarding short-term risk, UTI is less volatile compared to SKIL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check SKIL's competition here
UTI vs LFS Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LFS has a market cap of 51.8M. Regarding current trading prices, UTI is priced at $40.17, while LFS trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LFS's P/E ratio is 18.00. In terms of profitability, UTI's ROE is +0.13%, compared to LFS's ROE of +0.77%. Regarding short-term risk, UTI is more volatile compared to LFS. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LFS's competition here
UTI vs ONE Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ONE has a market cap of 51.3M. Regarding current trading prices, UTI is priced at $40.17, while ONE trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas ONE's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to ONE's ROE of +2.36%. Regarding short-term risk, UTI is less volatile compared to ONE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ONE's competition here
UTI vs STG Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, STG has a market cap of 42.3M. Regarding current trading prices, UTI is priced at $40.17, while STG trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas STG's P/E ratio is 0.78. In terms of profitability, UTI's ROE is +0.13%, compared to STG's ROE of +0.40%. Regarding short-term risk, UTI is less volatile compared to STG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check STG's competition here
UTI vs RYET Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, RYET has a market cap of 38.5M. Regarding current trading prices, UTI is priced at $40.17, while RYET trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas RYET's P/E ratio is -8.77. In terms of profitability, UTI's ROE is +0.13%, compared to RYET's ROE of -10.11%. Regarding short-term risk, UTI is less volatile compared to RYET. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYET's competition here
UTI vs AIU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AIU has a market cap of 37.6M. Regarding current trading prices, UTI is priced at $40.17, while AIU trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas AIU's P/E ratio is 0.51. In terms of profitability, UTI's ROE is +0.13%, compared to AIU's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to AIU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AIU's competition here
UTI vs YQ Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, YQ has a market cap of 21.9M. Regarding current trading prices, UTI is priced at $40.17, while YQ trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas YQ's P/E ratio is -0.99. In terms of profitability, UTI's ROE is +0.13%, compared to YQ's ROE of -0.46%. Regarding short-term risk, UTI is less volatile compared to YQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check YQ's competition here
UTI vs GNS Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GNS has a market cap of 18.7M. Regarding current trading prices, UTI is priced at $40.17, while GNS trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GNS's P/E ratio is -0.41. In terms of profitability, UTI's ROE is +0.13%, compared to GNS's ROE of -0.37%. Regarding short-term risk, UTI is more volatile compared to GNS. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GNS's competition here
UTI vs GEHI Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GEHI has a market cap of 18.3M. Regarding current trading prices, UTI is priced at $40.17, while GEHI trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GEHI's P/E ratio is -0.24. In terms of profitability, UTI's ROE is +0.13%, compared to GEHI's ROE of -0.90%. Regarding short-term risk, UTI is less volatile compared to GEHI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GEHI's competition here
UTI vs AACG Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AACG has a market cap of 16.7M. Regarding current trading prices, UTI is priced at $40.17, while AACG trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas AACG's P/E ratio is -4.77. In terms of profitability, UTI's ROE is +0.13%, compared to AACG's ROE of -0.90%. Regarding short-term risk, UTI is more volatile compared to AACG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check AACG's competition here
UTI vs EDTK Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, EDTK has a market cap of 15.8M. Regarding current trading prices, UTI is priced at $40.17, while EDTK trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas EDTK's P/E ratio is -12.37. In terms of profitability, UTI's ROE is +0.13%, compared to EDTK's ROE of -0.19%. Regarding short-term risk, UTI is more volatile compared to EDTK. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check EDTK's competition here
UTI vs IH Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, IH has a market cap of 13.9M. Regarding current trading prices, UTI is priced at $40.17, while IH trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas IH's P/E ratio is 5.00. In terms of profitability, UTI's ROE is +0.13%, compared to IH's ROE of +0.10%. Regarding short-term risk, UTI is less volatile compared to IH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check IH's competition here
UTI vs BTCT Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, BTCT has a market cap of 12.8M. Regarding current trading prices, UTI is priced at $40.17, while BTCT trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas BTCT's P/E ratio is -1.22. In terms of profitability, UTI's ROE is +0.13%, compared to BTCT's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to BTCT. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check BTCT's competition here
UTI vs TEDU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TEDU has a market cap of 12.2M. Regarding current trading prices, UTI is priced at $40.17, while TEDU trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas TEDU's P/E ratio is -2.40. In terms of profitability, UTI's ROE is +0.13%, compared to TEDU's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to TEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TEDU's competition here
UTI vs ASPU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ASPU has a market cap of 10.7M. Regarding current trading prices, UTI is priced at $40.17, while ASPU trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas ASPU's P/E ratio is -0.41. In terms of profitability, UTI's ROE is +0.13%, compared to ASPU's ROE of +0.19%. Regarding short-term risk, UTI is more volatile compared to ASPU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ASPU's competition here
UTI vs VEDU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, VEDU has a market cap of 9.3M. Regarding current trading prices, UTI is priced at $40.17, while VEDU trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas VEDU's P/E ratio is -1.91. In terms of profitability, UTI's ROE is +0.13%, compared to VEDU's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to VEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VEDU's competition here
UTI vs WAFU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, WAFU has a market cap of 7.7M. Regarding current trading prices, UTI is priced at $40.17, while WAFU trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas WAFU's P/E ratio is -57.93. In terms of profitability, UTI's ROE is +0.13%, compared to WAFU's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to WAFU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check WAFU's competition here
UTI vs TCTM Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TCTM has a market cap of 4.9M. Regarding current trading prices, UTI is priced at $40.17, while TCTM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas TCTM's P/E ratio is -0.15. In terms of profitability, UTI's ROE is +0.13%, compared to TCTM's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to TCTM. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TCTM's competition here
UTI vs TWOU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TWOU has a market cap of 4.4M. Regarding current trading prices, UTI is priced at $40.17, while TWOU trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas TWOU's P/E ratio is -0.01. In terms of profitability, UTI's ROE is +0.13%, compared to TWOU's ROE of -0.88%. Regarding short-term risk, UTI is less volatile compared to TWOU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TWOU's competition here
UTI vs CLEU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, CLEU has a market cap of 3.5M. Regarding current trading prices, UTI is priced at $40.17, while CLEU trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas CLEU's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.13%, compared to CLEU's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to CLEU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CLEU's competition here
UTI vs METX Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, METX has a market cap of 3.1M. Regarding current trading prices, UTI is priced at $40.17, while METX trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas METX's P/E ratio is 0.79. In terms of profitability, UTI's ROE is +0.13%, compared to METX's ROE of -0.04%. Regarding short-term risk, UTI is less volatile compared to METX. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check METX's competition here
UTI vs EEIQ Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, EEIQ has a market cap of 2.8M. Regarding current trading prices, UTI is priced at $40.17, while EEIQ trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas EEIQ's P/E ratio is -1.36. In terms of profitability, UTI's ROE is +0.13%, compared to EEIQ's ROE of -0.34%. Regarding short-term risk, UTI is less volatile compared to EEIQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check EEIQ's competition here
UTI vs FEDU Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, FEDU has a market cap of 2.4M. Regarding current trading prices, UTI is priced at $40.17, while FEDU trades at $10.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas FEDU's P/E ratio is 18.64. In terms of profitability, UTI's ROE is +0.13%, compared to FEDU's ROE of +0.00%. Regarding short-term risk, UTI is less volatile compared to FEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FEDU's competition here
UTI vs KIDZ Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, KIDZ has a market cap of 1.9M. Regarding current trading prices, UTI is priced at $40.17, while KIDZ trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas KIDZ's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to KIDZ's ROE of -2.81%. Regarding short-term risk, UTI is less volatile compared to KIDZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZ's competition here
UTI vs MYND Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, MYND has a market cap of 1.8M. Regarding current trading prices, UTI is priced at $40.17, while MYND trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas MYND's P/E ratio is -0.32. In terms of profitability, UTI's ROE is +0.13%, compared to MYND's ROE of -9.96%. Regarding short-term risk, UTI is less volatile compared to MYND. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check MYND's competition here
UTI vs GV Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GV has a market cap of 1.1M. Regarding current trading prices, UTI is priced at $40.17, while GV trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GV's P/E ratio is -0.07. In terms of profitability, UTI's ROE is +0.13%, compared to GV's ROE of -1.38%. Regarding short-term risk, UTI is less volatile compared to GV. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GV's competition here
UTI vs RYB Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, RYB has a market cap of 1M. Regarding current trading prices, UTI is priced at $40.17, while RYB trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas RYB's P/E ratio is 1.87. In terms of profitability, UTI's ROE is +0.13%, compared to RYB's ROE of +0.05%. Regarding short-term risk, UTI is less volatile compared to RYB. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYB's competition here
UTI vs GSUN Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GSUN has a market cap of 751.7K. Regarding current trading prices, UTI is priced at $40.17, while GSUN trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GSUN's P/E ratio is -0.21. In terms of profitability, UTI's ROE is +0.13%, compared to GSUN's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to GSUN. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GSUN's competition here
UTI vs AMBO Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AMBO has a market cap of 340.6K. Regarding current trading prices, UTI is priced at $40.17, while AMBO trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas AMBO's P/E ratio is 4.11. In terms of profitability, UTI's ROE is +0.13%, compared to AMBO's ROE of +0.39%. Regarding short-term risk, UTI is less volatile compared to AMBO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AMBO's competition here
UTI vs KIDZW Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, KIDZW has a market cap of 194.4K. Regarding current trading prices, UTI is priced at $40.17, while KIDZW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas KIDZW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to KIDZW's ROE of -2.81%. Regarding short-term risk, UTI is less volatile compared to KIDZW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZW's competition here
UTI vs LXEH Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LXEH has a market cap of 101.1K. Regarding current trading prices, UTI is priced at $40.17, while LXEH trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas LXEH's P/E ratio is -0.17. In terms of profitability, UTI's ROE is +0.13%, compared to LXEH's ROE of -0.15%. Regarding short-term risk, UTI is less volatile compared to LXEH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LXEH's competition here
UTI vs JZ Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, JZ has a market cap of 82.4K. Regarding current trading prices, UTI is priced at $40.17, while JZ trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas JZ's P/E ratio is -0.29. In terms of profitability, UTI's ROE is +0.13%, compared to JZ's ROE of -0.06%. Regarding short-term risk, UTI is less volatile compared to JZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check JZ's competition here
UTI vs FCHL Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, FCHL has a market cap of 45K. Regarding current trading prices, UTI is priced at $40.17, while FCHL trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas FCHL's P/E ratio is -0.04. In terms of profitability, UTI's ROE is +0.13%, compared to FCHL's ROE of +2.18%. Regarding short-term risk, UTI is less volatile compared to FCHL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FCHL's competition here
UTI vs BTCTW Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, BTCTW has a market cap of 15.5K. Regarding current trading prices, UTI is priced at $40.17, while BTCTW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas BTCTW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to BTCTW's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to BTCTW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check BTCTW's competition here
UTI vs APOL Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, APOL has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while APOL trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas APOL's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to APOL's ROE of -0.08%. Regarding short-term risk, UTI is more volatile compared to APOL. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check APOL's competition here
UTI vs RSHL Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, RSHL has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while RSHL trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas RSHL's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to RSHL's ROE of N/A. Regarding short-term risk, Volatility data is not available for a full comparison. UTI has daily volatility of 6.27 and RSHL has daily volatility of N/A.Check RSHL's competition here
UTI vs GPX Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GPX has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while GPX trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas GPX's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to GPX's ROE of +0.03%. Regarding short-term risk, UTI is more volatile compared to GPX. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GPX's competition here
UTI vs HMHC Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, HMHC has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while HMHC trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas HMHC's P/E ratio is 12.54. In terms of profitability, UTI's ROE is +0.13%, compared to HMHC's ROE of +0.01%. Regarding short-term risk, UTI is more volatile compared to HMHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HMHC's competition here
UTI vs HLG Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, HLG has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while HLG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas HLG's P/E ratio is 5.29. In terms of profitability, UTI's ROE is +0.13%, compared to HLG's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to HLG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HLG's competition here
UTI vs ZVO Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ZVO has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while ZVO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas ZVO's P/E ratio is -0.08. In terms of profitability, UTI's ROE is +0.13%, compared to ZVO's ROE of -1.07%. Regarding short-term risk, UTI is less volatile compared to ZVO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZVO's competition here
UTI vs NEW Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, NEW has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while NEW trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas NEW's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.13%, compared to NEW's ROE of -0.09%. Regarding short-term risk, UTI is less volatile compared to NEW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check NEW's competition here
UTI vs METXW Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, METXW has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while METXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas METXW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to METXW's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to METXW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check METXW's competition here
UTI vs FHS Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, FHS has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while FHS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas FHS's P/E ratio is 0.55. In terms of profitability, UTI's ROE is +0.13%, compared to FHS's ROE of N/A. Regarding short-term risk, UTI is less volatile compared to FHS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FHS's competition here
UTI vs ZME Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ZME has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while ZME trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas ZME's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.13%, compared to ZME's ROE of -1.88%. Regarding short-term risk, UTI is less volatile compared to ZME. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZME's competition here
UTI vs TTEI Comparison June 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TTEI has a market cap of 0. Regarding current trading prices, UTI is priced at $40.17, while TTEI trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 51.79, whereas TTEI's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to TTEI's ROE of -4.00%. Regarding short-term risk, Volatility data is not available for a full comparison. UTI has daily volatility of 6.27 and TTEI has daily volatility of N/A.Check TTEI's competition here